Sector: Financials | Industry: Corporate Financial Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5956 Sherry Lane, Suite 650 DALLAS TX 75225 |
Tel: | 1-917-9306343 |
Website: | https://www.swkhold.com |
IR: | See website |
Key People | ||
Joe D. Staggs President, Chief Executive Officer, Interim Chief Financial and Accounting officer |
Business Overview |
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company's segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform. |
Financial Overview |
For the fiscal year ended 31 December 2023, SWK Holdings Corp revenues decreased 9% to $37.8M. Net income increased 18% to $15.9M. Revenues reflect Pharmaceutical Development segment decrease of 80% to $1.2M. Net income reflects Change in fair value of acquisition-rela decrease from $5.2M (expense) to $6.3M (income), Pharmaceutical manufacturing, research decrease of 51% to $3.4M (expense). |
Employees: | 23 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $256.33M as of Dec 31, 2023 |
Annual revenue (TTM): | $37.76M as of Dec 31, 2023 |
EBITDA (TTM): | $21.18M as of Dec 31, 2023 |
Net annual income (TTM): | $15.89M as of Dec 31, 2023 |
Free cash flow (TTM): | $14.39M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $38.63M as of Dec 31, 2023 |
Shares outstanding: | 12,497,109 as of Mar 14, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |